Literature DB >> 31970867

Correlation between MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility: An updated meta-analysis.

Lele Yin1, Guo Shen2, Bin Zhu3.   

Abstract

BACKGROUND: The aim of this study was to investigate the correlation between MDM2 T309G single nucleotide polymorphism (SNP) and esophageal cancer susceptibility through pooling the open published data.
METHODS: By systematic searching the databases of Medline, EMBASE, CBM and CNKI, the case-control or cohort studies related to MDM2 T309G single nucleotide polymorphism and esophageal cancer risk were screened. Genetic phenotype data of T309G single nucleotide was extracted from the original included studies. The correlation between MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility was demonstrated by the odds ratio (OR) and its corresponding 95% confidence interval (95% CI). Publication bias was investigated by Egger's line regression test and begg's funnel plot.
RESULTS: After systematic searching of the relevant database, nine publications were finally included in the present study. The combined data demonstrated that the subjects with the G genotype had an increased risk of developing esophageal cancer in dominant (OR = 1.13, 95% CI: 1.00-1.27, P = 0.043), recessive (OR = 1.27, 95% CI: 1.12-1.45, P = 0.000) and homozygous (OR = 1.34, 95% CI:1.04-1.74, P = 0.024) genetic model through random or fixed data pooling method. Both begg's and Egger's line regression test indicated no significant publication bias.
CONCLUSION: Based on the present data, there was a significant correlation between MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility. Individuals with G genotype may have an increased risk of developing esophageal cancer.
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Esophageal cancer; MDM2 gene; meta-analysis; polymorphism; susceptibility

Mesh:

Substances:

Year:  2020        PMID: 31970867      PMCID: PMC7049506          DOI: 10.1111/1759-7714.13316

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


Introduction

Esophageal cancer is one of the most diagnosed malignant carcinoma of the digestive system. According to the latest statistical data of GLOBOCAN in 2018,1 there were approximately 570 000 new cases of esophageal cancer and 500 000 deaths, ranking the eighth incidence and seventh of all the malignant carcinomas. In year 2018, there were approximately 307 000 new cases of esophageal cancer and 283 000 deaths in China, ranking fifth in the incidence of malignant tumors and fourth in the mortality rate.2 As is already known, the development of esophageal cancer is the result of the interaction of genes and environmental factors, but the specific pathogenesis of both have not as yet been fully elucidated, and need further exploration.3 In recent years, studies have confirmed that gene single nucleotide polymorphism (SNP) was closely correlated with the cancer susceptibility.4 Murine double minute 2 (MDM2) locating in chromosome 12q15 encodes a nuclear‐localized E3 ubiquitin ligase. The encoded protein can promote tumor formation by targeting tumor suppressor proteins, such as p53, for proteasomal degradation. 309 T > G of MDM2 gene is a common SNP site for human beings and considered to correlate with cancer susceptibility. Chen and colleagues5 discussed the 309 T > G SNP and esophageal cancer risk and published their meta‐analysis in 2015. In that study,5 the author only included six studies. Since five years have now past, several new studies have been published which are relevant to MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility. Here, we provide an updated meta‐analysis relevant to MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility by adding new publications.

Methods

Electronic searching of databases

A systematic search of the electronic databases of Medline, EMBASE, CBM and CNKI was performed using the following subject terms: MDM2, murine double minute 2, esophageal, esophagus, carcinoma or cancer or malignancy or neoplasm or tumor or tumor, all related names to the specified SNP: rs2279744 or SNP309, or T309G by two reviewers (L.L. Yin & G. Shen), respectively. The publication screening procedure was performed according to Cochrane's handbook. The screening results were also cross‐checked by the two aforementioned reviewers. The references of the studies included were also carefully screened in order to identify potentially suitable publications.

Inclusion and exclusion criteria of studies

The publication inclusion criteria were as follows: (i) Case‐control or cohort studies relevant to MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility; (ii) papers were published in English or Chinese; (iii) the cases were patients diagnosed with esophageal cancer by pathology or cytology; and (iv) genotyping was correct. Publication exclusion criteria was as follows: (i) Case report or literature review publications relevant to MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility; (ii) studies published in other languages; (iii) duplicated publishing data; (iv) esophageal cancer not confirmed by pathology or cytology; and (v) the genotype of GG, TG and TT could not be directly extracted or calculated from the original studies.

Data extraction

The general information and genotyping data of each individual study was individually extracted by two reviewers (G. Shen and B. Zhu). The main information such as first author, journal, control type and Hardy‐Weinberg equilibrium of the control group were extracted from the original included studies. The genotype of MDM2 T309G distribution were also extracted and cross checked.

Statistical analysis

Stata11.0SE was applied for data analysis. The correlation between MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility was expressed by the odds ratio (OR) and 95% CI. The statistical heterogeneity was assessed by I2 test. The OR was combined through the random or fixed effect method. The publication bias was evaluated by begg's funnel plot and Egger's line regression test.

Results

Main characteristics of studies included

Nine studies6, 7, 8, 9, 10, 11, 12, 13, 14 relevant to MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility fulfilled the inclusion criteria and were included in the meta‐analysis (Fig 1). Of the nine publications included, eight patients were of Asian origin and one of Caucasian origin. Five studies used population based healthy controls and the other four used hospital‐based controls. The main characteristics of the nine studies included are showed in Table 1.
Figure 1

The publication electronic searching flow chart.

Table 1

Main information of the nine original studies

CaseControl
AuthorYearEthnicityControl typeTTTGGGTTTGGGHardy‐Weinberg equilibrium
Hong et al.2005AsianPopulation based203348207418711291Yes
Cao et al.2007AsianHospital based50170131117299226Yes
Liu et al.2010CaucasianPopulation based1161544117519980Yes
Ma et al.2012AsianPopulation based49119585011858Yes
Er et al.2012AsianHospital based473143417823Yes
Yang et al.2013AsianPopulation based1631261816112624Yes
Zhang et al.2015AsianPopulation based377025477114Yes
Er et al.2009AsianHospital based235132394621Yes
Li et al.2011AsianHospital based377025477114Yes
The publication electronic searching flow chart. Main information of the nine original studies

TG and GG genotype distribution

Before pooling the data, we first calculated the frequency of the TG and GG genotypes. The median TG and GG genotype frequency were 0.4843 and 0.2566 in the esophageal cancer group. For the control group, the median TG and GG genotype frequency were 0.5007 and 0.1762 (Fig 2).
Figure 2

Scatter plot of genotype distribution in esophageal cancer and control group. (a) TG genotype distribution between esophageal cancer and healthy controls; (b) GG genotype distribution between esophageal cancer and healthy controls.

Scatter plot of genotype distribution in esophageal cancer and control group. (a) TG genotype distribution between esophageal cancer and healthy controls; (b) GG genotype distribution between esophageal cancer and healthy controls.

Statistical heterogeneity

Statistical heterogeneity of each genetic model was assessed using the I2 test. For the dominant genetic model (GG + TG vs. TT), the statistical heterogeneity was not statistically different with the I2 = 36.6%, P = 0.125; However, for the recessive (GG vs. TT + TG, I2 = 69.9%, P = 0.001) and homozygous genetic models (GG vs. TT, I2 = 53.8%, P = 0.027), the statistical heterogeneity was statistically significant. Therefore, data was pooled through the fixed effect method in the dominant genetic model and the random effect method in the recessive and homozygous genetic models, respectively.

Data combination in dominant genetic model (TG + GG vs. TT)

Without statistical heterogeneity, the odds ratio for MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility was pooled by the fixed effect model. The combined OR = 1.13 (95% CI: 1.00–1.27, P = 0.043), which indicated subjects with TG or GG genotype had increased risk of developing esophageal cancer in the dominant genetic model (Fig 3).
Figure 3

Forest plot of OR in evaluation of the MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility through the fixed effect method in the dominant genetic model.

Forest plot of OR in evaluation of the MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility through the fixed effect method in the dominant genetic model.

Data combination in recessive genetic model (GG vs. TT + TG)

In the recessive genetic model, the data was pooled by the random effect method. The combined OR = 1.27 (95% CI: 1.12–1.45, P = 0.000), which demonstrated the subjects with GG genotype were more susceptible to esophageal cancer compared with the TT or TG genotype in the recessive genetic model (Fig 4).
Figure 4

Forest plot of OR in evaluation of the MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility through the random effect method in the recessive genetic model.

Forest plot of OR in evaluation of the MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility through the random effect method in the recessive genetic model.

Data combination in homozygous genetic model (GG vs. TT)

With regard to the homozygous genetic model (GG vs. TT), the OR was combined by the random effect method because of statistical heterogeneity across the nine original publications. The pooled OR = 1.34 (95% CI:1.04–1.74, P = 0.024), which indicated subjects with GG genotype had an increased risk of developing esophageal cancer in the homozygous genetic model (Fig 5).
Figure 5

Forest plot of OR in evaluation of the MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility through the random effect method in the homozygous genetic model.

Forest plot of OR in evaluation of the MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility through the random effect method in the homozygous genetic model.

Publications bias evaluation

The publication bias of the aforementioned three genotypes was assessed through begg's funnel plot and Egger's line regression test. The begg's funnel plot was generally left‐right symmetrical in the dominant (Fig 6), recessive (Fig 7) and homozygous (Fig 8) genetic model. The Egger's line regression test also indicated no significant publication bias (Table 2).
Figure 6

Begg's funnel plot was used to investigate publication bias in the dominant genetic model (GG + TG vs. TT).

Figure 7

Begg's funnel plot was used to investigate publication bias in the recessive genetic model (GG vs. TT + TG).

Figure 8

Begg's funnel plot was used to investigate publication bias in the homozygous genetic model (GG vs. TT).

Table 2

Egger's line regression test for evaluation the publication bias

Genetic modelCoefficientSE t value P‐value95% CI
Dominant0.6681.2280.540.603−2.23 to 3.57
Recessive0.4991.5470.320.756−3.15 to 3.55
Homozygous0.4851.2950.370.719−2.58 to3.55
Begg's funnel plot was used to investigate publication bias in the dominant genetic model (GG + TG vs. TT). Begg's funnel plot was used to investigate publication bias in the recessive genetic model (GG vs. TT + TG). Begg's funnel plot was used to investigate publication bias in the homozygous genetic model (GG vs. TT). Egger's line regression test for evaluation the publication bias

Discussion

In the present updated meta‐analysis, nine case‐control studies relevant to MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility were included. There were eight studies on patients of Asian origin and only one publication on a patient of Caucasian origin. The pooled data showed there was a significant correlation between MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility. This indicated that subjects with the G genotype had an increased risk of developing esophageal cancer in dominant (OR = 1.13, P = 0.043), recessive (OR = 1.27, P = 0.000) and homozygous (OR = 1.34, P = 0.024) genetic models through the random or fixed method. Chen and colleagues discussed the 309 T > G SNP and esophageal cancer risk by meta‐analysis in year 2015 and found that MDM2 T309G SNP was correlated with esophageal cancer susceptibility. Compared with the previously published meta‐analysis performed by Chen et al. our study added three new publications with increased statistical power and achieved the same conclusion. MDM2 is itself transcriptionally‐regulated by p53.15 Overexpression or amplification of this gene has been detected in a variety of malignant carcinomas.16, 17 Studies have also determined that MDM2 309 T > G SNP were also correlated with an increased risk of solid tumors. Luan et al. reported that MDM2 T309 G polymorphism may contribute to NSCLC susceptibility, especially in the Asian population and women.18 Li et al. found that the GG genotype of MDM2 SNP309 was significantly associated with an increased endometrial cancer risk by the meta‐analysis.19 In our meta‐analysis, we also confirmed the G allele could increase the esophageal cancer susceptibility, which was in accordance with previous publications. However, the exact mechanism of how MDM2 T309 G SNP affects cancer susceptibility has not yet been fully elucidated. Knappskog and colleagues found that MDM2 T309 G SNP affected cancer risk through modulation of Sp1 transcription factor binding.20 Other researchers reported that key SNP changes of MDM2 may have a large impact on the activity of p53‐dependent tumor suppression. Although the exact pathogenesis of how SNP changes MDM2 and cancer susceptibility are not fully understood, a significant correlation between MDM2 T309 G SNP and esophageal cancer has been confirmed by our present meta‐analysis. However, the present study has several limitations that need to be considered. First, only studies published in English or Chinese were searched and included in the meta‐analysis. This may have limited the number of potential articles retrieved. Second, only three new studies have been added to the work compared to the previous meta‐analysis. Third, due to the significant heterogeneity across the included studies, the statistical power was limited.

Disclosure

The authors confirm that there are no conflicts of interest.
  16 in total

Review 1.  Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk.

Authors:  Stian Knappskog; Per E Lønning
Journal:  Transcription       Date:  2011 Sep-Oct

2.  Association of genetic polymorphisms in MDM2, PTEN and P53 with risk of esophageal squamous cell carcinoma.

Authors:  Juan Ma; Jianna Zhang; Tao Ning; Ziping Chen; Changqing Xu
Journal:  J Hum Genet       Date:  2012-02-16       Impact factor: 3.172

3.  Impact of MDM2, TP53 and P14ARF Polymorphisms on Endometrial Cancer Risk and Onset.

Authors:  Wioletta Wujcicka; Agnieszka Zając; Grzegorz Stachowiak
Journal:  In Vivo       Date:  2019 May-Jun       Impact factor: 2.155

4.  Association of p53 and MDM2 polymorphisms with risk of human papillomavirus (HPV)-related esophageal squamous cell carcinoma (ESCC).

Authors:  Ju Yang; Bo Liu; Wen Li; Huihua Xiong; Hong Qiu; Qiang Fu; Bei Chen; Guangyuan Hu; Xianglin Yuan
Journal:  Cancer Epidemiol       Date:  2013-07-06       Impact factor: 2.984

5.  The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma.

Authors:  Yuan Hong; Xiaoping Miao; Xuemei Zhang; Fang Ding; Aiping Luo; Yongli Guo; Wen Tan; Zhihua Liu; Dongxin Lin
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

6.  Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.

Authors:  Shanghai Yu; Dongguang Qin; Sanjeev Shangary; Jianyong Chen; Guoping Wang; Ke Ding; Donna McEachern; Su Qiu; Zaneta Nikolovska-Coleska; Rebecca Miller; Sanmao Kang; Dajun Yang; Shaomeng Wang
Journal:  J Med Chem       Date:  2009-12-24       Impact factor: 7.446

7.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 8.  What have we learned from Linxian esophageal cancer etiological studies?

Authors:  Shao-Ming Wang; Christian C Abnet; You-Lin Qiao
Journal:  Thorac Cancer       Date:  2019-03-29       Impact factor: 3.500

9.  Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?

Authors:  Rui-Mei Feng; Yi-Nan Zong; Su-Mei Cao; Rui-Hua Xu
Journal:  Cancer Commun (Lond)       Date:  2019-04-29

10.  Correlation of HER2, MDM2, c-MYC, c-MET, and TP53 Copy Number Alterations in Circulating Tumor Cells with Tissue in Gastric Cancer Patients: A Pilot Study

Authors:  Fatemeh Nevisi; Marjan Yaghmaie; Hossein Pashaiefar; Kamran Alimoghaddam; Masoud Iravani; Gholamreza Javadi; Ardeshir Ghavamzadeh
Journal:  Iran Biomed J       Date:  2019-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.